Does Capmatinib have a significant impact on liver function?

Capmatinib (Capmatinib) is a MET exon 14 skipping mutation (METex14 ) and MET amplified selective tyrosine kinase inhibitors, widely used to treat patients with certain types of non-small cell lung cancer (NSCLC). As an oral targeted therapy drug, its pharmacokinetic characteristics and metabolic pathways mainly depend on the liver, so its impact on liver function is one of the key issues in patient management.

First of all, judging from clinical trial data, capmatinib does cause an increase in liver enzymes (ALT, AST) in some patients. In key clinical studies such as GEOMETRY mono-1, a certain proportion of patients experienced mild to moderate liver function abnormalities. Although most cases are reversible and non-fatal, attention still needs to be paid, especially in patients with poor liver function who are more likely to aggravate the condition.

Secondly, the metabolism of capmatinib is mainly carried out by the CYP3A4 enzyme in the liver. Therefore, patients with hepatic insufficiency have a reduced ability to metabolize and clear the drug, which may lead to an increase in drug concentration, thereby increasing the risk of adverse reactions. For patients with moderate or severe hepatic impairment, the risks should be carefully evaluated and dosage adjustments may be necessary. During treatment, liver function indicators need to be closely monitored to detect and deal with abnormal changes in a timely manner.

In addition, for patients with other liver diseases (such as chronic hepatitis B, cirrhosis) or who are receiving other drugs that may damage the liver, they should be more vigilant about drug-drug interactions and hepatotoxicity additive effects when using capmatinib. If patients take CYP3A4 inhibitors or inducers at the same time, it may affect the concentration and efficacy of capmatinib in the body, and may also increase the metabolic burden on the liver.

Reference materials:https://www.drugs.com/